Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bard CFO Todd Schermerhorn to retire

This article was originally published in Clinica

Executive Summary

CR Bard's chief financial officer Todd Schermerhorn has announced plans to retire, after 26 years with the company. He will continue to serve as CFO during a transition period expected to last until the end of this month, while his successor is elected. Mr Schermerhorn joined Bard in 1985 as a financial analyst, and held various financial positions until he was promoted to CFO in April 2003 (www.clinica.co.uk, 7 March 2003). The news of his retirement comes soon after Murray Hill, New Jersey-based Bard reported a disappointing second quarter, making a net loss of $47.8m after incurring litigation charges related to its recalled hernia products (www.clinica.co.uk, 25 July 2011). The company recorded 8% year-on-year revenue growth, at $725m, but was hampered by challenging conditions in its domestic market, where sales were up just 3%.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel